Home > About Us > Leadership

Leadership and Advisors

The Kv1.3 Therapeutics team combines industry experts, experienced scientists, and leading advisors to guide our clinical programs.  Key members of the management team include


Craig Philips – Interim Chief Executive Officer for Kv1.3 Therapeutics

Mr. Philips has over 30 years of pharmaceutical experience in the US and overseas with large, intermediate and start-up companies. His career includes experience with development and commercialization of both small molecules and biologic agents in a variety of sectors including: oncology, autoimmune diseases, cardiovascular disorders, viral diseases, dermatology and others. He spent the early part of his career with Bristol Myers and held senior positions at both Schering Plough (now Merck), and Bayer Pharmaceuticals. He was President at Cell Therapeutics, a company focused on new cancer therapies.

In 2012, he accepted an invitation to serve as Entrepreneur-in-Residence at the University of Washington where he worked with staff and faculty to advance the spinout and licensing of several life science and emerging technology platforms. He received a BSBA and MBA from The Ohio State University.   He currently a member of the Board of Directors for several private biotech companies.

Eric Tarcha – Vice President Translational Development at Kineta

Dr. Tarcha is a founding scientist at Kineta and heads translational development programs. This includes non-clinical and clinical activities to progress lead therapeutics through formal preclinical development and into first in man studies. He and his team are directly responsible for all in vitro and in vivo pharmacology studies including pharmacokinetic-pharmacodynamic characterization, toxicology, assay development, and clinical operations across all of Kineta’s development programs. Dr. Tarcha and his team are also responsible for CMC related activities including drug substance and product manufacturing, analytical assay development, formulations, and quality systems.

Dr. Tarcha received his B.S. and M.S. degrees in Medical Technology and Clinical Laboratory Sciences at Michigan State University and earned his PhD in Microbiology and Immunology from the Medical University of Ohio at Toledo. Prior to Kineta, he was a scientist at Illumigen Biosciences leading efforts in assay development, in vivo pharmacology and process development for a novel biologic antiviral therapy.

Ken North – Senior Vice President of Corporate Development at Kineta

Ken North heads corporate development and is responsible for generating financing for Kineta and its drug development programs.  Mr. North manages the Kineta finance department and also contributes to high level financial and strategic planning.

Prior to joining Kineta in 2008, Mr. North spent nearly thirty years managing financial institutions. Most recently, he served as founding President and CEO at Seattle Bank and was instrumental in launching and licensing the bank at its inception and leading the bank to become the nation’s most profitable bank of its size in 2007. Before that, Mr. North held key leadership positions at Metropolitan Savings Bank and was responsible for generating and managing $350 million in deposits. He gives back generously to many important community organizations holding leadership roles and serving on boards. Mr. North currently serves as president of the Seattle Kiwanis Memorial Fund, providing funding and volunteer services to disadvantaged youth and fighting against human trafficking with the development of Redlight Traffic, a first in class app for citizens to report trafficking activity anonymously to authorities.


Shawn Iadonato – CEO Kineta

Prior to founding Kineta, Dr. Iadonato co-founded and served as CSO of Illumigen Biosciences, Inc. At Illumigen Biosciences, he pioneered their patented drug discovery platform which relied upon recruitment and screening of healthy populations and elucidation of their shared “wellness” genes. Dr. Iadonato also led the successful discovery and preclinical development of Illumigen’s anti-hepatitis C drug, which ultimately led to the sale of the company in December, 2007 to Cubist Pharmaceuticals (now part of Merck & Co.). Before Illumigen, Dr. Iadonato managed the Human Genome Center at the University of Washington. He is co-inventor on more than 35 U.S. patents or patent applications. He is Principal Investigator or co-Investigator on numerous ongoing government grants and contracts. Dr. Iadonato received a Ph.D. in Genetics from the University of Washington and is a graduate of the University of Pennsylvania.

Dr. Shawn Iadonato serves as Kineta’s Chief Executive Officer. Dr. Iadonato is a co-founder of Kineta and previously served as Chief Scientific Officer. Under his leadership as CSO, the Kineta pipeline expanded to include the AViiD Screening Platform and multiple novel drug with a focus on immuno-oncology, antivirals and chronic pain.

Michael O. Banks – Chief Financial Officer Kineta

Mike Banks leads the financial functions for Kineta and its subsidiaries. Mr. Banks has over 35 years of financial and operational leadership experience.

Prior to joining Kineta, Mr. Banks was the CFO at Trupanion, Inc. where he led the company’s initial public offering. Before Trupanion, Mr. Banks was the CFO at Penn Millers Holding Corp where he also led that company’s initial public offering. Mr. Banks has experience with strategic planning, financial and treasury operations, investment portfolio management, public company reporting and compliance, performance management systems, capital raising and management, enterprise risk management, acquisitions and divestitures, investor relations, human resources and operating experiencing overseeing business units in the companies he has worked at.

Mr. Banks graduated from the University of Delaware and started his career working at KPMG, where he obtained his license as a CPA in New Jersey.

Dan Raymond –

Gavin Jancke – General Manager of Engineering for Microsoft Research

Gavin Jancke has been in an engineering leadership role for the entirety of his 25 year career at Microsoft Corporation. Currently he is General Manager of Engineering for Microsoft Research where he built and currently runs the Central Engineering Group for the division, serving the engineering needs of several hundred PhD computer science researchers. His engineering team composed of software engineers, program managers, designers, quality assurance, and hardware & electrical engineers, serves the need of transforming researcher ideas from conception to reality. During the 15 years in this role, his group has completed over 500 engineering projects spanning research prototypes through to technology transfers into products such as Windows, Office, XBox, Azure and others.

Prior to Microsoft Research Mr. Jancke worked for Bill Gates as a member of his technical advisory staff working on a variety of research projects in the fields of Search and Telephony which have eventually become integrated into products such as Desktop Search and Office Communicator. Prior to that he worked as a Development Manager for Microsoft SQL Server, spanning several versions of the product from V4.2 through V7.0. There he lead the engineering effort for the graphical administration and query tools for the product line.

Mr. Jancke has had 10 US patents awarded, half dozen patent applications still pending and has published papers in various computer science academic conferences in the fields of Human Computer Interaction, Communication, and Storage. In addition to his leadership role he is still an active engineer contributing in the areas of mobile and desktop applications, cloud and firmware development.

Luke Fouke – CEO of American Research Corporation

Luke Fouke is the Co-Founder of American Research Capital LLC and currently serves as CEO. American Research Capital provides structured debt financing to businesses performing research under federally sponsored research contracts. Previously Luke spent five years raising angel equity and debt for a biopharmaceutical company. Luke worked as a commercial banker at Southwest Bank of St. Louis, as a Senior Equity Analyst for Friedman Billings Ramsey in Washington DC and Delafield Hambrecht in Seattle. He holds a BA in History and Spanish from Denison University and a MBA from The Olin School of Business at Washington University. Luke is married with three children and resides in St. Louis.